Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
-
- Danuta M Skowronski
- University of British Columbia, Vancouver, Canada
-
- Catharine Chambers
- British Columbia Centre for Disease Control, Vancouver, Canada
-
- Gaston De Serres
- Centre Hospitalier Universitaire de Québec, Québec, Canada
-
- James A Dickinson
- University of Calgary, Calgary, Canada
-
- Anne-Luise Winter
- Public Health Ontario, Toronto, Canada
-
- Rebecca Hickman
- British Columbia Centre for Disease Control, Vancouver, Canada
-
- Tracy Chan
- British Columbia Centre for Disease Control, Vancouver, Canada
-
- Agatha N Jassem
- University of British Columbia, Vancouver, Canada
-
- Steven J Drews
- University of Alberta, Edmonton, Canada
-
- Hugues Charest
- Institut National de Santé Publique du Québec, Québec, Canada
-
- Jonathan B Gubbay
- University of Toronto, Toronto, Canada
-
- Nathalie Bastien
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
-
- Yan Li
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
-
- Mel Krajden
- University of British Columbia, Vancouver, Canada
説明
<jats:p>Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): −14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.</jats:p>
収録刊行物
-
- Eurosurveillance
-
Eurosurveillance 23 (5), 2018-02-01
European Centre for Disease Control and Prevention (ECDC)
